Business
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates
HENDERSON, Nev., May 08, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates.
About this update from Zura Bio Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/318f11067f0fe8179762cd706ab0482f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fvQA849pztDs.4RQAwIulg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/318f11067f0fe8179762cd706ab0482f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/iYkPnTyCH_EjnBRqH5MBjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/318f11067f0fe8179762cd706ab0482f","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Advanced the Phase 2 TibuSURE clinical trial evaluating tibulizumab in adults with systemic sclerosis (SSc)","length":107,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Continued preparations for the planned Phase 2 trial evaluating tibulizumab in adults with hidradenitis suppurativa (HS), expected to initiate in Q2 2025","length":153,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strengthened the team with a strategic appointment to support clinical execution and organizational growth","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"$170.6 million in cash and cash equivalents with cash runway anticipated through 2027","length":85,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":451,"olType":false},{"type":"text","content":"HENDERSON, Nev., May 08, 2025--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates.","length":389,"tagName":"p"},{"type":"text","content":""The first quarter of 2025 reflected steady progress across our clinical and operational priorities," said Robert Lisicki, Chief Executive Officer of Zura Bio. "We continued advancing trial efforts for our Phase 2 TibuSURE trial for adults with SSc, and progressed preparations for the initiation of a second Ph...